2021 Press Releases

Cognition Therapeutics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in connection with Initial Public Offering

November 15, 2021

Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone

November 15, 2021

Cognition Therapeutics Announces Pricing of Upsized Initial Public Offering

October 8, 2021

Cognition Therapeutics Announces Launch of its Initial Public Offering

October 4, 2021

Cognition Therapeutics Announces Election of Jack Khattar Chairman of the Board

April 20, 2021

Cognition Therapeutics to Present Corporate and Clinical Update at H.C. Wainwright Global Life Sciences Conference

March 3, 2021

Cognition Therapeutics Publishes Biomarker Findings from Clinical Study of CT1812 Supporting Positive Impact on Synapse Biology

February 9, 2021

Cognition Therapeutics Publishes Evidence Identifying Receptor Integral in Parkinson’s Disease Pathology

February 1, 2021

Cognition Therapeutics Reviews 2020 Accomplishments and Provides 2021 Guidance

January 5, 2021

Cognition Therapeutics Appoints Brett P. Monia to its Board of Directors

October 27, 2020

Cognition Therapeutics Elucidates Genetic Mutation that Protects Against Alzheimer’s Disease

October 19, 2020

Cognition Therapeutics Appoints Industry Veteran Jack Khattar to its Board of Directors

September 9, 2020

Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study of CT1812

August 27, 2020

Cognition Therapeutics Receives $75.8 Million NIA Grant for 540-Patient Phase 2 Study of CT1812 in Collaboration with the Alzheimer’s Clinical Trials Consortium

June 8, 2020

Cognition Therapeutics Announces Change in Leadership

March 27, 2020

Cognition Therapeutics Announces Publication Analyzing Biomarkers of Synapse Damage or Loss to Support Future Therapeutic Development Efforts in Alzheimer’s Disease

March 17, 2020

Cognition Therapeutics to Give Webcast Presentation at Annual Piper Jaffray Healthcare Conference on December 3, 2019

November 20, 2019

Cognition Therapeutics Expands Leadership Team with Appointment of James M. O’Brien as Chief Financial Officer

November 4, 2019

Cognition Therapeutics Sponsoring Satellite Symposium on “Sigma-2 Receptors: Role in Health and Disease” during Society for Neuroscience Annual Meeting

October 15, 2019

Cognition Therapeutics to Present Findings from the Elayta™ Clinical Development Program at Society for Neuroscience Annual Meeting

October 10, 2019

Cognition Therapeutics’ Founder/CSO to Provide Update on Elayta™ Clinical Progress at ADDF Alzheimer’s Drug Discovery Conference

September 10, 2019

Cognition Therapeutics to Give Webcast Presentation at 3rd Annual Janney Healthcare Conference on September 9, 2019

September 4, 2019

Cognition Therapeutics Extends IP Coverage of Alzheimer’s Therapeutic Elayta™ to Additional Major Pharmaceutical Markets with Patent Issuances in Japan and China

July 24, 2019

Cognition Therapeutics Receives $3.3 Million NIA Grant to Conduct qEEG Study of Elayta™ with World-Leading Alzheimer’s Biomarker Experts

July 9, 2019

Cognition Therapeutics Appoints Anthony O. Caggiano M.D., Ph.D. to the Position of Chief Medical Officer

June 5, 2019

Cognition Therapeutics Expands Clinical Expertise on Medical Advisory Board with Addition of Drs. Mary Sano and Philip Scheltens

April 5, 2019

Cognition Therapeutics Elects Lisa Ricciardi to its Board of Directors

March 26, 2019

Cognition Therapeutics Receives European Patent Covering its Alzheimer’s Disease Candidate, Elayta™

February 21, 2019

Cognition Therapeutics Announces Publication of Complete Results from Phase 1 Clinical Trial of Elayta™

February 19, 2019

Elayta is an investigational product and neither its use nor the tradename has been approved by the FDA.